{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:44:58Z","timestamp":1788245098152,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Chemosaturation with percutaneous hepatic perfusion (CS-PHP; Hepatic CHEMOSAT\u00ae Delivery System; Delcath Systems Inc, USA) is a novel interventional procedure, which delivers high doses of melphalan directly to the liver in patients with liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. We have previously shown promising efficacy for patients with ocular melanoma (OM) and cholangiocarcinoma (CCA) within our single-center and multi-center experiences. The aim of this study was to analyze the safety and efficacy of CS-PHP after 141 treatments at Hannover Medical School, Germany.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Overall response rates (ORR) were assessed according to Response Evaluation Criteria In Solid Tumors (RECIST1.1). Median Overall survival (mOS), median progression-free survival (mPFS), and median hepatic PFS (mhPFS) were analyzed using the Kaplan\u2013Meier estimation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 60 patients were treated with CS-PHP in the salvage setting from October 2014 until January 2019 at Hannover Medical School with a total of 141 procedures. Half of the patients were patients with hepatic metastases of ocular melanoma (OM) (<jats:italic>n<\/jats:italic>\u2009=\u200930), 14 patients had CCA (23.3%), 6 patients had hepatocellular carcinoma (10%), and 10 patients were treated for other secondary liver malignancies (16.7%). In total, ORR and disease stabilization rate were 33.3% and 70.3% (<jats:italic>n<\/jats:italic>\u2009=\u200925), respectively. ORR was highest for patients with OM (42.3%), followed by patients with CCA (30.8%). Independent response-associated factors were normal levels of lactate dehydrogenase (odds ratio (OR) 13.7; <jats:italic>p<\/jats:italic>\u2009=\u20090.015) and diagnosis with OM (OR 9.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.028). Overall, mOS was 9\u00a0months, mPFS was 4\u00a0months, and mhPFS was 5\u00a0months. Patients with OM had the longest mOS, mPFS, and mhPFS with 12, 6, and 6\u00a0months, respectively. Adverse events included most frequently significant, but transient, hematologic toxicities (80% of grade 3\/4 thrombopenia), less frequently hepatic injury up to liver failure (3.3%) and cardiovascular events including two cases of ischemic insults (5%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Salvage treatment with CS-PHP is safe and effective particularly in patients OM and CCA. Careful attention should be paid to possible, serious hepatic, and cardiovascular complications.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00432-020-03289-5","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T06:02:27Z","timestamp":1592632947000},"page":"3003-3012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma"],"prefix":"10.1007","volume":"146","author":[{"given":"Leon","family":"Sch\u00f6nfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-4083","authenticated-orcid":false,"given":"Martha M.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"3289_CR1","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Macarulla Mercade T, Javle M, et al (2019) ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Presented at ESMO 2019.","DOI":"10.1093\/annonc\/mdz394.027"},{"key":"3289_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh D-Y, Dotan E, Catenacci DV, Van Cutsem E, Lihou C, Zhen H, F\u00e9liz L, Vogel A (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol."},{"key":"3289_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1245\/ASO.2005.05.003","volume":"12","author":"HR Alexander Jr","year":"2005","unstructured":"Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12:138\u2013144","journal-title":"Ann Surg Oncol"},{"key":"3289_CR4","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-009-0482-9","volume":"16","author":"HR Alexander Jr","year":"2009","unstructured":"Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM et al (2009) Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16:1852\u20131859","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3289_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","volume":"19","author":"C Artzner","year":"2019","unstructured":"Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A, Eigentler T, Syha R, Gr\u00f6zinger G (2019) Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 19(1):31","journal-title":"Cancer Imaging"},{"issue":"131\u2013150","key":"3289_CR6","first-page":"ix","volume":"12","author":"BR Blechacz","year":"2008","unstructured":"Blechacz BR, Gores GJ (2008) Cholangiocarcinoma. Clin Liver Dis 12(131\u2013150):ix","journal-title":"Clin Liver Dis"},{"issue":"2","key":"3289_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"3289_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1245\/ASO.2004.07.004","volume":"11","author":"ED Feldman","year":"2004","unstructured":"Feldman ED, Pingpank JF, Alexander HR Jr (2004a) Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11:290\u2013297","journal-title":"Ann Surg Oncol"},{"key":"3289_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.gassur.2003.11.005","volume":"8","author":"ED Feldman","year":"2004","unstructured":"Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK et al (2004b) Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8:200\u2013207","journal-title":"J Gastrointest Surg"},{"issue":"20","key":"3289_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"key":"3289_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","volume":"136","author":"AC Grover","year":"2004","unstructured":"Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr (2004) Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136:1176\u20131182","journal-title":"Surgery"},{"key":"3289_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23:1309\u20131319","journal-title":"Ann Surg Oncol"},{"key":"3289_CR13","first-page":"1230","volume":"6","author":"P Jovanovic","year":"2013","unstructured":"Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6:1230\u20131244","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"3289_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","volume":"143","author":"MM Kirstein","year":"2017","unstructured":"Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, Wacker F, Vogel A (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 143(10):2113\u20132121","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3289_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/jcm9010056","volume":"9","author":"M K\u00f6hler","year":"2019","unstructured":"K\u00f6hler M, Harders F, Loh\u00f6fer F, Paprottka PM, Schaarschmidt BM, Theysohn J, Herrmann K, Heindel W, Schmidt HH, Pascher A, Stegger L, Rahbar K, Wildgruber M (2019) Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with Yttrium-90 radioembolization. J Clin Med 9(1):56","journal-title":"J Clin Med"},{"issue":"12","key":"3289_CR16","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25(12):2328\u20132338","journal-title":"Ann Oncol"},{"issue":"15","key":"3289_CR17","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","volume":"37","author":"A Lamarca","year":"2019","unstructured":"Lamarca A, Palmer HP, Wasan HS, Ross PJ, Ting Ma Y, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Waters JS, Hobbs C, Barber S, Ryder D, Ramage J, Davies LM, Bridgewater JA, Valle JW, ABC-06 (2019) A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin\/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced\/metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy. J Clin Oncol 37(15):4003\u20134003","journal-title":"J Clin Oncol"},{"issue":"1","key":"3289_CR18","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):052\u2013060","journal-title":"Semin Liver Dis"},{"issue":"4","key":"3289_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","volume":"29","author":"S Marquardt","year":"2019","unstructured":"Marquardt S, Kirstein MM, Br\u00fcning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK (2019) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 29(4):1882\u20131892","journal-title":"Eur Radiol"},{"issue":"6","key":"3289_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","volume":"42","author":"TS Meijer","year":"2019","unstructured":"Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei LF, Kapiteijn E, de Leede EM, Martini CH, van der Meer RW, Tijl FGJ, Vahrmeijer AL (2019) Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath systems' second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol 42(6):841\u2013852","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3289_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00270-013-0826-5","volume":"37","author":"FM Moeslein","year":"2014","unstructured":"Moeslein FM, McAndrew EG, Appling WM, Hryniewich NE, Jarvis KD, Markos SM, Sheets TP et al (2014) Evaluation of Delcath Systems\u2019 Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37:763\u2013769","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3289_CR22","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465\u20133474","journal-title":"J Clin Oncol"},{"issue":"14","key":"3289_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"key":"3289_CR24","doi-asserted-by":"crossref","unstructured":"van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, et al (2018) Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19:1127-1134","DOI":"10.1093\/annonc\/mdn032"},{"issue":"10","key":"3289_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F, Lotz G, Ferrucci P (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 186(10):937\u2013944","journal-title":"Rofo"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03289-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T23:24:06Z","timestamp":1624145046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03289-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Arndt Vogel has received honoraria from Delcath Systems Inc for Advisiory Boards and speaker activities. Frank Wacker reports grants and personal fees from Delcath Systems, Inc. during the conduct of the study; grants from Siemens Healthineers, Promedicus Ltd., and personal fees from Novartis Pharma GmbH,\u00a0outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}